Osteosarcoma

HC Beird, SS Bielack, AM Flanagan, J Gill… - Nature reviews Disease …, 2022 - nature.com
Osteosarcoma is the most common primary malignant tumour of the bone. Osteosarcoma
incidence is bimodal, peaking at 18 and 60 years of age, and is slightly more common in …

Recent advances in zinc oxide nanoparticles (ZnO NPs) for cancer diagnosis, target drug delivery, and treatment

S Anjum, M Hashim, SA Malik, M Khan, JM Lorenzo… - Cancers, 2021 - mdpi.com
Simple Summary Despite breakthroughs in medicine, cancer remains one of the most feared
diseases. Traditionally, chemotherapies have been the treatment of choice. However …

Osteosarcoma: a review of current and future therapeutic approaches

X Zhao, Q Wu, X Gong, J Liu, Y Ma - Biomedical engineering online, 2021 - Springer
Osteosarcoma (OS) is the most common primary bone malignancy that affects children and
young adults. OS is characterized by a high degree of malignancy, strong invasiveness …

A comprehensive review on barium titanate nanoparticles as a persuasive piezoelectric material for biomedical applications: prospects and challenges

A Sood, M Desseigne, A Dev, L Maurizi, A Kumar… - Small, 2023 - Wiley Online Library
Stimulation of cells with electrical cues is an imperative approach to interact with biological
systems and has been exploited in clinical practices over a wide range of pathological …

Current and future therapeutic approaches for osteosarcoma

DJ Harrison, DS Geller, JD Gill, VO Lewis… - Expert review of …, 2018 - Taylor & Francis
Introduction: Current treatment of osteosarcoma includes surgical resection of all gross
disease in conjunction with systemic chemotherapy to control micro-metastatic disease. This …

Future directions in the treatment of osteosarcoma

MW Bishop, KA Janeway, R Gorlick - Current opinion in pediatrics, 2016 - journals.lww.com
Future directions in the treatment of osteosarcoma : Current Opinion in Pediatrics Future
directions in the treatment of osteosarcoma : Current Opinion in Pediatrics Log in or Register …

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children's Oncology Group

PA Meyers, CL Schwartz, MD Krailo… - Journal of clinical …, 2008 - ascopubs.org
Purpose To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate
with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the …

Therapeutic importance of kaempferol in the treatment of cancer through the modulation of cell signalling pathways

MY Qattan, MI Khan, SH Alharbi, AK Verma… - Molecules, 2022 - mdpi.com
Plant-derived flavonoids are considered natural nontoxic chemo-preventers and have been
widely studied for cancer treatment in recent decades. Mostly all flavonoid compounds show …

Primary bone osteosarcoma in the pediatric age: state of the art

A Longhi, C Errani, M De Paolis, M Mercuri… - Cancer treatment …, 2006 - Elsevier
The current combination treatment, chemotherapy and surgery, has significantly improved
the cure rate and the survival rate of primary bone osteosarcoma. The 5-year survival rate …